Literature DB >> 1277217

Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.

U Draeger, H J Hohorst.   

Abstract

The permeation kinetics of cyclophosphamide and its metabolites were studied with Ehrlich ascites tumor cells, murine L1210 leukemia cells, and mouse L929 fibroblasts at 1 degrees C. In contrast to carboxyphosphamide and nor-nitrogen mustard, an equipartition of cyclophosphamide and 4-hydroperoxycyclophosphamide was observed in these cells. First experiments have been done to study the efflux of cyclophosphamide and 4-hydroperoxycyclophosphamide after incubation until saturation with Ehrlich ascites tumor cells. Cyclophosphamide could be washed out completely, whereas, 4-hydroperoxyclophosphamide shows an apparent retention in the cell at 37 degrees C.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277217

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  8 in total

1.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

2.  Macromolecular DNA-damage in murine and human leukemic and lymphoid cells after in vitro exposure to ASTA Z 7557 (INN mafosfamide).

Authors:  R Osieka; R Pannenbäcker; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

4.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

5.  [Permeability of N,N-bis(2-chloroethyl)-diamido-phosphoric-acid into tumor cells (author's transl)].

Authors:  U Lenssen; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1979-02-19       Impact factor: 4.553

6.  Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.

Authors:  H H Gerhartz; E Liss; H Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1979-07-27       Impact factor: 4.553

7.  Does acrolein contribute to the cytotoxicity of cyclophosphamide?

Authors:  E Wrabetz; G Peter; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 8.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.